Changes in lipoprotein(a), LDL-cholesterol and apolipoprotein B in homozygous familial hypercholesterolaemic patients treated with dextran sulfate LDL-apheresis

Eur J Clin Invest. 1993 Dec;23(12):819-26. doi: 10.1111/j.1365-2362.1993.tb00736.x.

Abstract

We evaluated the effect of periodical treatment with LDL-apheresis by adsorption to dextran sulfate (Liposorber LA-15) on several aspects related to LDL and Lipoprotein(a) metabolisms, in three homozygous familial hypercholesterolaemic patients with LDL receptor deficiency. The dextran sulfate columns retained apolipoprotein B-containing particles with high affinity and capacity, in such a way that the treatment of a volume of plasma equivalent to three times the patient plasma volume resulted in an 85% decrease of circulating LDL-cholesterol and Lipoprotein(a). The continuous treatment with LDL-apheresis was highly beneficial for these patients since an average plasma concentration lower than 200 mg dl-1 for LDL-cholesterol, and lower than 25 mg dl-1 for Lipoprotein(a) could be achieved by treating the patients once a week. After each apheresis treatment, plasma concentrations of these metabolites progressively returned to the pretreatment, steady-state, levels. The analysis of the rates of return allowed us to estimate the fractional catabolic rates. FCRs of LDL-cholesterol were 0.052, 0.049 and 0.047 pools day-1, and those of apolipoprotein B, 0.065, 0.045 and 0.050 pools day-1 in the three subjects, respectively. These values are much lower than those in normolipidaemic individuals as observed by others, and are in accordance with the LDL-receptor deficiency condition of our patients. Two of them had highly elevated Lipoprotein(a) plasma concentrations, and their FCRs of Lipoprotein(a) were calculated to be 0.112 and 0.066 pools day-1.(ABSTRACT TRUNCATED AT 250 WORDS)

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Apolipoproteins B / analysis*
  • Blood Component Removal*
  • Child
  • Cholesterol, LDL / blood*
  • Dextran Sulfate*
  • Female
  • Homozygote
  • Humans
  • Hyperlipoproteinemia Type II / blood
  • Hyperlipoproteinemia Type II / therapy*
  • Lipoprotein(a) / blood*
  • Male
  • Receptors, LDL / deficiency
  • Regression Analysis

Substances

  • Apolipoproteins B
  • Cholesterol, LDL
  • Lipoprotein(a)
  • Receptors, LDL
  • Dextran Sulfate